Novel benzimidazole-based pseudo-irreversible butyrylcholinesterase inhibitors with neuroprotective activity in an Alzheimer's disease mouse model - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue RSC Medicinal Chemistry Année : 2022

Novel benzimidazole-based pseudo-irreversible butyrylcholinesterase inhibitors with neuroprotective activity in an Alzheimer's disease mouse model

Philipp Spatz
Thomas Zimmermann
Sophie Steinmüller
Julian Hofmann
  • Fonction : Auteur
Michael Decker

Résumé

Benzimidazole-based inhibitors of butyrylcholinesterase were designed and tested for their activity and selectivity in vitro , leading to compound (11d) that attenuated Aβ 25-35 -induced learning impairments in an Alzheimer's disease mouse model.

Dates et versions

hal-04267435 , version 1 (01-11-2023)

Identifiants

Citer

Philipp Spatz, Thomas Zimmermann, Sophie Steinmüller, Julian Hofmann, Tangui Maurice, et al.. Novel benzimidazole-based pseudo-irreversible butyrylcholinesterase inhibitors with neuroprotective activity in an Alzheimer's disease mouse model. RSC Medicinal Chemistry, 2022, 13 (8), pp.944-954. ⟨10.1039/d2md00087c⟩. ⟨hal-04267435⟩
11 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More